🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with glp-1 and peripheral arterial disease?

Has anyone dealt with glp-1 and peripheral arterial disease?

traveltech_sara Fri, Jan 31, 2025 at 6:48 PM 24 replies 2,011 viewsPage 1 of 5
This thread is more than 16 months old. Information may be outdated. Consider searching for more recent discussions.
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Jan 31, 2025 at 8:13 PM#1

Just had to share this with someone who would understand — has anyone dealt with glp-1 and.

Got my latest A1C and I am genuinely emotional right now. 12 months in and the progress is real.

Details in the comments but wanted to start this thread because I think others going through the same thing need to see that it works.

48 14MeganSA_TX, LarryQC_SD, wanda_boise and 45 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jan 31, 2025 at 8:30 PM#2

To answer the question about Has anyone dealt with glp-1 and peripheral arterial disease? — in my experience this comes down to a few key factors.

I have been dealing with this for several months now, and what I have found is that individual responses really do vary. That said, the general consensus on Has anyone dealt with glp-1 seems solid.

What specifically worked for me: tracking everything in a spreadsheet. I would suggest traveltech_sara try the same approach and reporting back.

27 9roxy_nash, tony_orlando, Dr.NephBHM_UK and 24 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Jan 31, 2025 at 8:47 PM#3
BariatricNurseD said:
— in my experience this comes down to a few key factors

Completely agree with BariatricNurseD. I would add that Has anyone dealt with glp-1 also has implications for body composition that sometimes get overlooked in these discussions.

In my case, following a similar approach led to fewer side effects compared to what I was doing before.

5 8RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 2 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Jan 31, 2025 at 9:04 PM#4

Subscribing to this thread. Has anyone dealt with is exactly what I've been researching. 🙏

41 5sophie_paris, mel_PDX, Dr.AddMedPHL and 38 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jan 31, 2025 at 9:21 PM#5

As a healthcare provider, I want to add some clinical context to this discussion on Has anyone dealt with glp-1 and.

Building on what traveltech_sara said — the evidence base here is well-established. The key publications to reference are from the STEP program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
41 22BrianDallas92, labquiet_amy, emily_PDX and 38 others
Reply Quote Save Share Report
1235

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register